Active Biotech AB Interim report January - March 2015

Laquinimod

• The pivotal CONCERTO clinical study is continuing according to plan and results are expected in 2016
• Teva is holding a number of presentations of laquinimod at the AAN Annual Meeting on April 18-25 

Tasquinimod     

• Results from the Phase III study 10TASQ10 showed that treatment with tasquinimod reduced the risk of radiographic cancer progression or death compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with metastatic castration resistant prostate cancer (mCRPC) who have not received chemotherapy, but did not extend overall survival (OS, HR=1.09, CI 95%: 0.94 - 1.28)
• Further development of tasquinimod for the treatment of prostate cancer has been discontinued. The collaboration agreement with Ipsen will accordingly cease.

ISI          

• The project is currently focusing on building up a patent portfolio

Financial summary

MSEK	Jan. - Mar.			Jan. - Dec.
	2015	2014		2014
Net sales	2.9	2.1		10.4
Operating loss	-57.4	-59.2		-228.5
Loss for the period	-58.0	-60.2		-231.5
Loss per share (SEK)	-0.64	-0.80		-3.02
Cash and cash equivalents	270.5	298.5		328.5

 For further information, please contact:                    

Tomas Leanderson, President and CEO  Tel: [phone]     Hans Kolam, CFO  Tel: [phone]  The report is also available at www.activebiotech.com

Active Biotech AB(Corp. Reg. No. 556223-9227)Box 724, SE-220 07 LundTel: [phone]Fax: [phone]

Active Biotech AB Interim report January - March 2015 http://hugin.info/1002/R/1913651/683571.pdf

HUG#1913651